Physician profile
Benjamin Miriovsky
NPI 1427234277
$4,748.75
in general payments reported to CMS, 2019-2025
42 companies · $1,685 in 2025
The $1,685 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.04 · 2021: $11.92 · 2022: $889 · 2023: $785 · 2024: $1,365 · 2025: $1,685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,715 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,714.80 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $120.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $751.63 | 2022-2025 | |
| Pfizer INC. | $605.26 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $488.34 | 2022-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Seagen INC. | $381.72 | 2022-2023 | Tukysa, Padcev, Adcetris |
| Janssen Biotech, INC. | $300.68 | 2022-2025 | Tecvayli, Darzalex, Rybrevant |
| E.R. Squibb & Sons, L.L.C. | $256.85 | 2022-2025 | Opdivo, Krazati, Augtyro |
| Celgene Corporation | $145.43 | 2023-2024 | Reblozyl, Pomalyst |
| Daiichi Sankyo INC. | $141.86 | 2024-2025 | Enhertu |
| Abbvie INC. | $128.77 | 2024-2025 | |
| Beone Medicines USA, INC. | $127.10 | 2025 | Brukinsa, Tevimbra |
| Gilead Sciences, INC. | $113.16 | 2021-2025 | Trodelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.21 | 2024-2025 | Gilotrif |
| Pharmacyclics LLC, An Abbvie Company | $93.60 | 2022-2023 | Imbruvica |
| Glaxosmithkline, LLC. | $91.14 | 2022-2025 | Ojjaara, Zejula, Jemperli |
| Aveo Pharmaceuticals, INC. | $90.86 | 2022-2025 | Fotivda |
Show all 41 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Miriovsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.